Skip to main content

Table 1 Baseline characteristics of all patients related to the diagnoses pFM or axSpA or PsA with cFM or without FM

From: Performance of standardized patient reported outcomes developed for spondyloarthritis in primary and concomitant forms of fibromyalgia

 

FM

axSpA-

p-value axSpA- vs. FM

axSpA+

p-value axSpA + vs. FM

PsA-

p-value PsA- vs. FM

PsA+

p-value PsA + vs. FM

Age

56.4 ± 10.2

53.5 ± 14.2

0.086

48.7 ± 13.5

0.026

56.0 ± 13.2

< 0.001

58.5 ± 10.4

0.962

Male

2%

67%

< 0.001

0%

---

38%

< 0.001

6%

---

HLAB27 pos.

0%

84%

---

71%

---

16%

---

50%

---

CRP (mg/dl)

0.3 ± 0.5

1.1 ± 2.1

0.001

0.5 ± 0.3

0.035

1.4 ± 3.0

0.001

0.5 ± 0.5

0.031

NRS pain

7.5 ± 1.6

6.1 ± 2.4

< 0.001

7.7 ± 1.8

0.768

6.4 ± 2.2

< 0.001

7.3 ± 1.1

0.223

  1. Fibromyalgia (FM); axial spondyloarthritis (axSpA); psoriatic arthritis (PsA)
  2. axSpA-: axSpA without concomitant FM (cFM), axSpA+: axSpA with cFM, PsA-: PsA without cFM, PsA+: PsA with cFM
  3. HLA B27: human leucocyte antigen B27; CRP: C-reactive protein; NRS: numerical rating scale